People with higher levels of 'good' cholesterol (HDL) before starting GLP-1 agonists are more likely to lose weight, possibly because higher HDL reflects better overall metabolic health.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether baseline HDL cholesterol consistently predicts greater weight loss on GLP-1 RAs across multiple RCTs, adjusting for BMI, HbA1c, and insulin resistance.
A systematic review and meta-analysis of RCTs of GLP-1 RAs in adults with obesity and type 2 diabetes, stratifying participants by baseline HDL (<40 mg/dL vs. ≥40 mg/dL), and pooling standardized mean differences in weight loss at 52 weeks.
Whether individuals with low vs. high baseline HDL have significantly different weight loss on the same GLP-1 RA regimen when matched for BMI and HbA1c.
A multicenter RCT enrolling 300 adults with type 2 diabetes and BMI ≥30 kg/m², randomized to semaglutide 2.4 mg/week, stratified by baseline HDL (<40 vs. ≥40 mg/dL), matching for BMI and HbA1c, measuring weight change at 52 weeks as primary outcome.
Whether baseline HDL predicts greater weight loss over time in adults initiating GLP-1 RA therapy in real-world settings, independent of BMI and HbA1c.
A prospective cohort study following 2,500 adults with type 2 diabetes initiating GLP-1 RA therapy, measuring baseline HDL, BMI, HbA1c, and tracking weight change annually for 3 years, adjusting for confounders.
Whether, at a single time point, individuals who achieved ≥5% weight loss on GLP-1 RAs have higher baseline HDL than those who did not.
A cross-sectional analysis of 4,000 adults in a national health database who used GLP-1 RAs, comparing baseline HDL between those who achieved ≥5% weight loss and those who did not, adjusting for BMI and HbA1c.
Whether exceptional weight loss on GLP-1 RAs consistently occurs in individuals with high baseline HDL.
A case series of 30 patients with type 2 diabetes who lost >15% of body weight on GLP-1 RA therapy, documenting baseline HDL and comparing to 30 matched controls who lost <5%.